“Is the open mouth mightier than the needle?” Dr. Peter Martin on Ibrutinib for MCL Patients

In the latest issue of Blood, Dr. Peter Martin writes about the latest use of ibrutinib for patients with mantle cell lymphoma.

Unknown's avatar

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment